Read More

Small-Cap Firm Century Therapeutics’ Expands into Autoimmune Diseases, Analyst Says Clade Therapeutics Acquisition Intriguing

Century Therapeutics unveils plans to expand CNTY-101 clinical development into additional autoimmune diseases, including systemic lupus erythematosus. $60 million private placement supports R&D activities. Acquisition of Clade Therapeutics enhances pipeline with iPSC-focused programs.

IPSC

Read More

Vertex’s Alpine Acquisition: Unpacking Analyst Predictions on Povetacicept’s Potential Impact

Vertex Pharmaceuticals to acquire Alpine Immune Sciences for $4.9 billion, expanding into nephrology with promising APOL1-mediated kidney disease treatments. Analysts foresee significant revenue growth potential, with Alpine's lead molecule poised to add over $5 billion in sales.

ALPN